Targeted Biologics to Boost Asthma Treatment Market Value to $23.1 Billion

The asthma treatment market value will grow from approximately $15.9 billion in 2013 across eight major countries (the US, UK, France, Germany, Spain, Italy, Japan, and Australia) to $23.1 billion by 2023, according to research and consulting firm GlobalData.

The company’s latest report, PharmaPoint: Asthma – Global Drug Forecast and Market Analysis to 2023, states that this increase, which represents a Compound Annual Growth Rate (CAGR) of 3.8%, will be driven largely by the expanding share of targeted biologics in the treatment of severe asthma.

Valentina Gburcik, PhD, Senior Analyst for GlobalData, says “While the market share of fixed-dose combinations of inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs) will shrink from almost half to 23%, targeted biologics will enter the market and start dominating the asthma space, accounting for 32% of total sales in 2023 from just 8.7% in 2013.The uptake of these novel drugs will offset the dip in sales caused by the recent patent expiry of Singulair, and that of numerous short-acting beta-agonist, ICS, and ICS/LABA products.”

The current late-stage asthma pipeline is dominated by biologics that target various inflammatory pathways in specific patient subpopulations. GlobalData states that the companies with the strongest drug pipelines are GlaxoSmithKline, AstraZeneca, Teva, Roche and Regeneron/Sanofi.

Ms. Gburcik adds “While the subpopulations targeted by pipeline biologics are limited in size, these novel agents will begin to fulfill the important unmet need for a personalized approach to the treatment of severe asthma. Despite the development of these biologics, a significant growth opportunity will persist for new patented products, especially lower-priced drugs with more convenient dosing, which will improve patient compliance.”

The report provides annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for 10 years to 2023, across eight major markets (the US, UK, France, Germany, Spain, Italy, Japan and Australia). Key topics covered include pipeline analysis, strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and industry drivers, restraints and challenges. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Its research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling them to offer the most relevant, reliable, and actionable strategic business intelligence available for a wide range of industries. For more information, please contact the Press Office on +44 (0)1204 543 537 or at pr@globaldata.com.